timothy sykes logo
CAPR Stock Rockets As FDA Extends Review And Cantor Lifts Target Thumbnail
G Google News

CAPR Stock Rockets As FDA Extends Review And Cantor Lifts Target

BRYCE TUOHEY•UPDATED AUG. 25, 2026, 12:32 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Capricor Therapeutics Inc. stocks have been trading up by 14.26 percent amid optimism over promising clinical trial progress.

Key Takeaways

  • Wall Street’s tone has flipped as Cantor Fitzgerald boosted its rating on CAPR to Overweight and hiked its price target to $28 from $3.50 after Q2 earnings.
  • Shares of Capricor Therapeutics exploded roughly 80–100% after traders cheered a favorable FDA stance on deramiocel and the company’s stronger-than-expected Q2 update.
  • After a 9–3 negative advisory panel vote on a cardiomyopathy claim, Capricor Therapeutics is refocusing deramiocel’s BLA on upper-limb function in DMD using 24‑month HOPE‑3 data.
  • The FDA extended the PDUFA decision date for deramiocel from 2026/08/22 to 2026/11/22, keeping CAPR’s regulatory pathway alive but pushing the key catalyst out.
  • Activist Kaos Capital is pressing Capricor Therapeutics’ board for strategic shifts, new directors, M&A exploration, and tighter cash discipline.

Candlestick Chart

Live Update At 12:32:00 EDT: On Tuesday, August 25, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 14.26%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics (CAPR) is trading like a classic binary biotech story. Over the past few weeks, the stock has ripped from the low $4s to close near $7.77, with multiple high‑range days and big gaps on regulatory headlines. For short‑term traders, that’s a clear signal the market is repricing CAPR around deramiocel’s new regulatory path.

The daily chart shows a sharp break from a long, flat base under $4.50. Once the FDA signaled it would review the amended BLA and Cantor turned bullish, CAPR pushed into the $6–$8 zone with heavy volatility. Intraday, the 5‑minute chart around the latest session shows tight consolidation between roughly $7.70 and $8.10 after an early spike toward $8.60. That intraday action tells traders that, for now, dip buyers are defending the mid‑$7s.

More Breaking News

Fundamentally, Capricor Therapeutics remains pre‑revenue. Q2 2026 results show no sales and a net loss of about $40.7M, with operating cash outflow around $31.5M. Yet CAPR holds roughly $237.9M in cash, cash equivalents, and short‑term investments, plus a strong current ratio near 7.4. Management says this runway covers at least 12 months, which matters for traders watching dilution risk into the November PDUFA date.

Why Traders Are Watching CAPR’s FDA Reset

Traders are glued to CAPR because the story has flipped from “almost dead” to “back in play” in a matter of days. After a 9–3 negative FDA advisory committee vote on deramiocel’s original cardiomyopathy indication in Duchenne muscular dystrophy, many assumed the Biologics License Application was effectively sunk. Instead, Capricor Therapeutics regrouped, leaned on its HOPE‑3 data, and pivoted.

The company is now amending the BLA to focus on upper‑limb skeletal muscle function in DMD, backed by 24‑month open‑label extension data and additional robustness analyses. That’s not a minor tweak; it’s a strategic reframing around the primary endpoint where deramiocel actually hit. The key is that the FDA has agreed to review this major amendment and extended the PDUFA action date to 2026/11/22. For CAPR, that new date is a hard binary catalyst.

The market’s reaction has been loud. CAPR surged more than 80% when news broke that the agency would actively review the amendment. Subsequent headlines confirming the PDUFA extension to November drove another pop of 4–8%, showing traders see “delay” as “more upside optionality,” not a red flag.

Layer on top the Cantor Fitzgerald upgrade: CAPR was lifted to Overweight from Neutral, and the price target exploded to $28 from $3.50, above the broader analyst mean near $26.12. That single move told the street that at least one major shop believes deramiocel’s upper‑limb story has real commercial potential. For momentum traders, that’s fuel.

There’s also a governance angle. Activist Kaos Capital, a sizable CAPR holder, is pressing for new independent directors, an M&A and Strategic Alternatives Committee, and tougher cash discipline. If deramiocel stumbles, pressure from Kaos raises the odds Capricor Therapeutics explores deals or other strategic moves. That optionality keeps CAPR on many watchlists, even for skeptics of the science.

Conclusion

Capricor Therapeutics now sits at the intersection of science, regulation, and trading psychology. CAPR is still a pre‑revenue biotech burning over $30M in operating cash in a quarter, with deeply negative returns on equity and assets. Yet it also carries about $237.9M in cash and short‑term investments and says it has at least a year of runway without counting on product revenue or a Priority Review Voucher sale. For active traders, that reduces near‑term dilution risk and keeps the focus squarely on the 2026/11/22 PDUFA date.

The deramiocel narrative has clearly shifted. After a bruising advisory panel loss, Capricor Therapeutics is leaning into its strongest data — upper‑limb function in DMD — and the FDA is willing to keep the BLA under active review. Cantor’s aggressive $28 target and Overweight call signal that not all on Wall Street are writing CAPR off. At the same time, activist pressure from Kaos Capital reminds traders that strategic change, board refreshes, or even M&A could enter the picture if the regulatory path breaks down.

For those studying CAPR, this is a textbook high‑volatility biotech setup: huge potential reward, very real binary risk. As Tim Sykes likes to say, “Trading isn’t about being right, it’s about managing risk so you can stay in the game.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. With Capricor Therapeutics, that means treating every FDA headline and every chart level as a possible turning point, not a guarantee. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”